DISCUSSION
tumor
TUMOR, METASTATIC GASTRIC CANCER, RECRUITMENT, GASTRIC CANCER
In this phase 2 study, which investigated the efficacy and safety of maintenance pamiparib in patients with platinum‐sensitive locally advanced or metastatic gastric cancer, the median PFS observed in the pamiparib arm was numerically higher than that in the placebo arm (3.7 months vs. 2.1 months, respectively); however, this PFS improvement did not reach statistical significance, nor did the difference in OS between treatment groups.The safety and tolerability profile of pamiparib in this study was consistent with that of pamiparib and PARPi in other tumor types and treatment settings.Due to the difficulty in recruiting this patient population, the study was converted from a phase 3 to a phase 2 trial, and was therefore not sufficiently powered for OS analysis. Possible reasons for low recruitment to this study include changes in the treatment landscape for gastric cancer, such as additional first‐line, second‐line, and third‐line treatment options which were not recommended at the time of study design in 2018.While some targeted agents have been approved for gastric cancer,